Conclusion
Since the discovery of HIV-2 in 1985, considerable progress has been made in understanding its virology and epidemiology. The data suggest differences between HIV-2 and HIV-1 in geographic distribution, distinct epidemic trends, perinatal transmission rates, and incubation periods to the development of AIDS. The virologic determination and mechanisms for these apparent biologic differences are still unknown. However, understanding how HIV-2 differs from HIV-1 is essential to interpretations of comparative virologic studies. We hope such comparative studies will yield important information on the pathogenic mechanisms employed by HIV viruses and will lead the way to the development of effective interventions for the prevention of AIDS. This is best exemplified in studies indicating that this close relative of HIV-1 infection, via its attenuated phenotype, may confer significant protection from subsequent infection by HIV-1. This further suggests that understanding HIV-2 immunity and cross-immunity may be useful for HIV vaccine design and development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barin F, Mboup S, Denis F, et al. Serological Evidence for Virus Related to Simian T-Lymphotropic Retrovirus III in Residents of West Africa. Lancet. 1985;2(8469–70):1387–1390.
Essex M, Kanki P. The Origins of the AIDS Virus. Sci Amer. 1988;259:64–71.
Gao F, Yue L, White A, et al. Human infection by genetically diverse SIVSM-related HIV-2 in West Africa. Nature. 1992;358:495–499.
Stahl Hennig C, Herchenroder O, Nick S, et al. Experimental infection of macaques with HIV-2ben, a novel HIV-2 isolate. AIDS. 1990;4:611–617.
Castro BA, Nepomuceno M, Lerche NW, et al. Persistent infection of baboons and rhesus monkeys with different strains of HIV-2. Virology. 1991;184(l):219–226.
Alter HJ, Eichberg JW, Masur H, et al. Transmission of HTLV-III from human plasma to chimpanzees: an animal model for AIDS. Science. 1984;226:549–552.
Francis DP, Feorino PM, Broderson JR, et al. Infection of chimpanzees with lymphadenopathy-associated virus. Lancet. 1984;2(8414):1276–1277.
Gajdusek DC, Amyx HL, Gibbs CJJ, et al. Infection of chimpanzees by human T-lymphotropic retroviruses in brain and other tissues from AIDS patients. Lancet. 1985;1(8419):55–56.
Fultz PN, McClure HM, Swenson RB, et al. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol. 1986;58(1):116–124.
Kanki P, McLane MF, King NWJ, et al. Serologic Identification and Characterization of a Macaque T-Lymphotropic Retrovirus Closely Related to HTLV-III. Science. 1985;228:1199–1201.
Kanki PJ, Kurth R, Becker W, et al. Antibodies to simian T-lymphotropic retrovirus type III in African green monkeys and recognition of STLV-III viral proteins by AIDS and related sera. Lancet. 1985;1(8441):1330–1332.
Essex M, Kanki P. Human Immunodeficiency Virus Type 2 (HIV-2). In: Broder S, Merigan T, Bologenesi D, eds. Textbook of AIDS Medicine. Baltimore: Williams & Wilkins; 1994:873–886.
Markovitz DM. Infection with the human immunodeficiency virus type-2. Ann Intern Med. 1993;118:211–218.
Kanki PJ. Human Immunodeficiency Virus Type 2, (HIV-2). AIDS Reviews. 1999;1(20):101–108.
Smith TF, Srinivasan A, Schochetman G, et al. The phylogenetic history of immunodeficiency viruses. Nature. 1988;333:573–575.
Myers G, MacInnes K, Korber B. The emergence of simian/human immunodeficiency viruses. AIDS Res Hum Retroviruses. 1992;8(3):373–386.
Marx P, Li Y, Lerche N, et al. Isolation of a simian immunodeficiency virus related to human immunodeficiency virus type 2 from a west African pet sooty mangabey. J Virol. 1991;65:4480–4485.
Emau P, McClure HM, Isahakia M, et al. Isolation from African Sykes’ monkeys (Cercopi-thecus mitis) of a lentivirus related to human and simian immunoeficiency viruses. J Virol. 1991;65(4): 2135–2140.
Allan JS, Kanda P, Kennedy RC, et al. Isolation and characterization of simian immunodeficiency viruses from two subspecies of African green monkeys. AIDS Res Hum Retroviruses. 1990;6:275–285.
Franchini G, Collalti E, Arya SK, et al. Genetic Analysis of a New Subgroup of Human and Simian T-Lymphotropic Retroviruses: HTLV-IV LAV-2, SBL6669, and STLV-IIIAGM. AIDS Res Hum Retroviruses. 1987;3:11–17.
Kanki P, Barin F, Mboup S, et al. Relationship of Simian T-Lymphotropic Virus Type III to Human Retroviruses in Africa. Antibiot Chemother. 1987;38:21–27.
Biberfeld G, Brown F, Esparza J, et al. Meeting Report, WHO working group on characterization of HIV-related, retroviruses: Criteria for characterization and proposal for a nomenclature system. AIDS. 1987;1:189–190.
Boeri E, Giri A, Lillo F, et al. In vivo genetic variability of the human immunodeficiency virus type 2 V3 region. J Virol. 1992;66:4546–4550.
Kirchhoff F, Jentsch KD, Bachmann B, et al. A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses. Virology. 1990;177:305–311.
Gao F, Yue L, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol. 1994:68:7433–7447.
Yamaguchi J, Devare S, Brennan C. Identification of a new HIV-2 subtype based on phylogenetic analysis of full-length genomic sequence. AIDS Res. Hum Retroviruses. 2000;16(9):925–930.
Sankalé JL, Sallier de la Tour R, Renjifo B, et al. Intra-patient Variability of the Human Immunodeficiency Virus Type-2 (HIV-2) Envelope V3 Loop. AIDS Res Hum Retroviruses. 1995;11(5):617–623.
Sarr AD, Sankale JL, Gueye-Ndiaye A, et al. Genetic analysis of HIV type 2 in monotypic and dual HIV infections. AIDS Res Hum Retroviruses. 2000;16(3):295–298.
Norrgren H, Marquina S, Leitner T, et al. HIV-2 genetic variation and DNA load in asymptomatic carriers and AIDS cases in Guinea-Bissau. JAIDS. 1997;16(l):31–38.
Peeters M, Koumare B, Mulanga C, et al. Genetic subtypes of HIV type 1 and HIV type 2 strains in commercial sex workers from Bamako, Mali. AIDS Res Hum Retroviruses. 1998;14(l):51–58.
Xiang Z, Ariyoshi K, Wilkins A, et al. HIV type 2 pathogenicity is not related to subtype in rural Guinea Bissau. AIDS Res Hum Retroviruses. 1997;13(6):501–505.
Dietrich U, Adamski M, Kreutz R, et al. A highly divergent HIV-2-related isolate. Nature. 1989;342:948–950.
Kawamura M, Katahira J, Fukasawa M, et al. Isolation and characterization of a highly divergent HIV-2[GH-2]: generation of an infectious molecular clone and functional analysis of its revresponsive element in response to primate retrovirus transactivators (Rev and Rex). Virology. 1992;188(2): 850–853.
Pieniazek D, Ellenberger D, Janini L, et al. Predominance of Human Immunodeficiency Virus Type 2 Subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses. 1999;15:603–608.
Kanki P. West African Human Retroviruses Related to STLV-III. AIDS. 1987;1:141–145.
Harrison LH, José da Silva AP, Gayle HD, et al. Risk factors for HIV-2 infection in Guinea-Bissau. JAIDS. 1991;4(11):1155–1160.
Naucler A, Albino P, Da Silva AP, et al. HIV-2 infection in hospitalized patients in Bissau, Guinea-Bissau. AIDS. 1990:5:301–304.
Denis F, Barin F, Gershy-Damet G, et al. Prevalence of Human T-Lymphotropic Retroviruses Type III (HIV) and Type IV in Ivory Coast. Lancet. 1987;1(8530):408–411.
Pepin J, Dunn D, Gaye I, et al. HIV-2 infection among prostitutes working in The Gambia: association with serological evidence of genital ulcer diseases and generalized lymphadenopathy. AIDS. 1991;5:69.
Romieu I, Marlink R, Kanki P, et al. HIV-2 link to AIDS in West Africa. JAIDS. 1990;3:220–230.
Naucler A, Andreasson PA, Costa CM, et al. HIV-2-associated AIDS and HIV-2 seroprevalence in Bissau, Guinea-Bissau. JAIDS. 1989;2:88–93.
Kanki P, DeCock KM. Epidemiology and Natural History of HIV-2. AIDS. 1994;8(supp.):S1–S9.
Kanki P, Marlink R, Siby T, et al. Biology of HIV-2 Infection in West Africa. In: Papas TS, ed. Gene. Regulation and AIDS. Houston: Portfolio Publishing Company of Texas; 1990:255–271.
Ankrah T, Roberts M, Antwi P, et al. The African AIDS case definition and HIV serology in medical in-patients at Komfo Anokye Teaching Hospital, Kumasi, Ghana. West Afr J Med. 1994;13:98.
Olaleye O, Bernstein L, Ekweozor C, et al. Prevalence of human immunodeficiency virus types 1 and 2 infections in Nigeria. J Infect Dis. 1993;167:710.
Maiga Y, Sissoko Z, Maiga M. Etude de la seroprevalence de l’Infection a VIH dans les 7 regions economiques du Mali. VIIIth International Conference on AIDS in Africa/VIIIth African Conference on Sexually Transmitted Diseases. Marrakech; 1993.
Anderson RM, May RM. The population biology of the interaction between HIV-1 and HIV-2: coexistence or competitive exclusion? AIDS. 1996;10(14):1663–1673.
Kanki P, Travers K, Hernandez-Avila M, et al. Slower Heterosexual Spread of HIV-2 Compared with HIV-1. Lancet. 1994;343:943–946.
Andreasson P, Dias F, Naucler A, et al. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS. 1993;7:989.
Ngagne M, Diouf A, Kebe F, et al. Histoire Naturelle de la transmission verticale VIH1 et VIH 2 a Dakar. IXth International Conference on AIDS and Associated Cancers in Africa; 1995: Kampala, Uganda.
Adjorlolo-Johnson G, DeCock K, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA. 1994;272:462–466.
Smallman-Raynor M, Cliff A. The Spread of Human Immunodeficiency Virus Type 2 into Europe: A Geographical Analysis. Intl J of Epi. 1991;20:480.
Santos-Ferreira M, Cohen T, Lourenco M, et al. A study of seroprevalence of HIV-1 and HIV-2 in six provinces of People’s Republic of Angola: clues to the spread of HIV infection. JAIDS. 1990;3:780.
Victorino RMM, Guerreiro D, Lourenço MH, et al. Prevalence of HIV-2 infection in a family planning clinic in Libson, Intl J STD AlDS. 1992;3:281–284.
Rubsamen-Waigmann H, Briesen H, Maniar J, et al. Spread of HIV-2 in India. Lancet. 1991;337:550–551.
Rubsamen-Waigmann H, Maniar J, Gerte S, et al. High proportion of HIV-2 and HIV-1/2 doublereactive sera in two Indian states, Maharashtra and Goa: first appearance of an HIV-2 epidemic along with an HIV-1 epidemic outside of Africa. Int J Med Microbiol Virol Parasitol Infect Dis. 1994;280:398–402.
Courouce AM, Barin F, Baudelot J, et al. HIV-2 infection among blood donors and other subjects in France. Transfusion. 1989;29:368.
Matheron S, Simon F, Sassi G, et al. Infection HIV-2 chez l’adulte; etude de cohorte; Paris: 1986–1993. VIIIth International Conference on AIDS in Africa and VIIIth African Conference on Sexually Transmitted Diseases; December 1993; Marrakech.
De Cock K, Brun-Vezinet F. Epidemiology of HIV-2 Infection. AIDS. 1989;3(supp 1):S89–S95.
Machuca A, Soriano V Gutierrez M, et al. Human immunodeficiency virus type 2 infection in Spain. The HIV-2 Spanish Study Group. Intervirology. 1999;42(1):37–42.
Zagury JF, Franchini G, Reitz M, et al. Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1. Proc Natl Acad Sci USA. 1988;85:5941–5945.
Tristem M, Mansinho K, Champalimaud JL, et al. Six new isolates of human immunodeficiency virus type 2 (HIV-2) and the molecular characterization of one (HIV-2CAM2). J Gen Virol. 1989;70:479–484.
Matsuda Z, Chou MJ, Matsuda M, et al. Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome. Proc Natl Acad Sci USA. 1988;85: 6968–6972.
Strebel K, Klimkait T, Maldarelli F, et al. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol. 1989;63:3784–3791.
Cohen EA, Terwilliger EF, Sodroski JG, et al. Identification of a protein encoded by the vpu gene of HIV-1. Nature. 1988;334:532–534.
Bour S, Strebel K. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol. 1996;70(12):8285–8300.
Franchini G, Fargnoli KA, Giombini F, et al. Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. Proc Natl Acad Sci. USA. 1989;86:2433–2437.
Yu XF, Ito S, Essex M, et al. A naturally immunogenic virion-associated protein specific for HIV-2 and SIV Nature. 1988;335:262–265.
Henderson L, Sowder R, Copeland T, et al. Isolation and characterization of a novel protein (X-ORF product) from SIV and HIV-2. Science. 1988;241:199–201.
Kappes J, Morrow C, Lee S, et al. Identification of a novel retroviral gene unique to human immunodeficiency virus type 2 and simian immunodeficiency virus SIVMAC. J Virol. 1988;62:3501–3505.
Moore JP. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS. 1990;4:297–305.
Morikawa Y, Moore JP, Fenouillet E, et al. Complementation of human immunodeficiency virus glycoprotein mutations in trans. J Gen Virol. 1992;73(Pt 8):1907–1913.
Bahraoui E, Benjouad A, Guetard D, et al. Study of the interaction of HIV-1 and HIV-2 envelope glycoproteins with the CD4 receptor and role of Nglycans. AIDS Res Hum Retroviruses. 1992;8(5):565–573.
Looney DJ, Hayashi S, Nicklas M, et al. Differences in the interaction of HIV-1 and HIV-2 with CD4. JAIDS. 1990;3:649–657.
Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272(5263):872–877.
Clapham P, McKnight A, Weiss RA. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol. 1992;66:3531–3537.
Endres MJ, Clapham PR, Marsh M, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell. 1996;87(4):745–756.
Bron R, Klasse PJ, Wilkinson D, et al. Promiscuous Use Of Cc and Cxc Chemokine Receptors In Cell-to-Cell Fusion Mediated By a Human Immunodeficiency Virus Type 2 Envelope Protein. J Virol. 1997;71(11):8405–8415.
Heredia A, Vallejo A, Soriano V, et al. Chemokine receptors and HIV-2 [letter], AIDS. 1997;11(9):1198–1199.
Evans L, Moreau J, Odehouri K, et al. Characterization of a Noncytopathic HIV-2 Strain with Unusual Effects on CD4 Expression. Science. 1988;240:1522–1525.
Kong L, Lee S, Kappes J, et al. West African HIV-2-related human retrovirus with attenuated cytopathicity. Science. 1988;240:1525–1529.
Albert J, Naucler A, Bottiger B, et al. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS. 1990;4(4):291–295.
Albert J, Stalhandske P, Marquina S, et al. Biological phenotype of HIV type 2 isolates correlates with V3 genotype. AIDS Res Hum Retroviruses. 1996;12(9):821–828.
Isaka Y, Sato A, Miki S, et al. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology. 1999;264(1):237–243.
Pichuantes S, Babe LM, Barr PJ, et al. Recombinant HIV2 protease processes HIV1 Pr53gag and analogous junction peptides in vitro. J Bio Chem. 1990;265:13890–13898.
Allan JS, Coligan JE, Lee TH, et al. Immunogenic Nature of a pol Gene Product of HTLV-III/LAV. Blood. 1987;69:331–333.
Bakhanashvili M, Hizi A. Fidelity of the RNAdependent DNA synthesis exhibited by the reverse transcriptases of human immunodeficiency virus types 1 and 2 and of murine leukemia virus: mispair extension frequencies. Biochemistry. 1992;31(39):9393–9398.
Taube R, Avidan O, Hizi A. The fidelity of misinsertion and mispair extension throughout DNA synthesis exhibited by mutants of the reverse transcriptase of human immunodeficiency virus type 2 resistant to nucleoside analogs. Euro J Biochem. 1997;250(1):106–114.
Hizi A, Tal R, Hughes SH. Mutational analysis of the DNA polymerase and ribonuclease H activities of human immunodeficiency virus types 2 reverse transcriptase expressed in Escherichia coli. Virology. 1991;180(1):339–346.
Hizi A, Tal R, Shaharabany M, et al. Catalytic properties of the reverse transcriptase of human immunodeficiency viruses type 1 and type 2. J Bio Chem. 1991;266(10):6230–6239.
Myers G, Pavlakis GN. Evolutionary potential of complex retroviruses. In: Levy JA, ed. The retroviridae. New York: Plenum Press; 1992:1–37.
Haseltine WA. The Molecular Biology of HIV-1. In: DeVita VT, Jr., Hellman S, Rosenberg SA, et al., eds. AIDS, Etiology, Diagnosis, Treatment and. Prevention. 3rd ed. Philadelphia: J.B. Lippincott Co.; 1992:39–59.
Markovitz DM, Hannibal M, Perez VL, et al. Differential regulation of human immunodeficiency viruses (HIVs): a specific regulatory element in HIV-2 responds to stimulation of the T-cell antigen receptor. Proc Natl Acad Sci USA. 1990;87(23):9098–9102.
Tong-Starksen S, Welsh T, Peterlin M. Differences in transcriptional enhancers of HIV-1 and HIV-2 response to T-cell activation signals. J Immunol. 1990;145:4348–4354.
Arya S, Gallo C. Human immunodeficiency virus type 2 long terminal repeat: Analysis of regulatory elements. AIDS. 1988;85:9753–9757.
Courgnaud V, Laure F, Fultz PN, et al. Genetic differences accounting for evolution and pathogencity of simian immunodeficiency virus from a sooty mangabey after cross-species transmission to a pigtailed macaque. J Virol. 1992;66:414–419.
Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987;326:711–713.
Arya SK. Human immunodeficiency virus type-2 gene expression: two enhancers and their activation by T-cell activators. New Biologist. 1990;2(1):57–65.
Fu GK, Markovitz DM. Purification of the pets factor. A nuclear protein that binds to the inducible TG-rich element of the human immunodeficiency virus type 2 enhancer. J Biol Chem. 1996;271(32):19599–19605.
Markovitz DM, Smith MJ, Hilfinger J, et al. Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and kappa B regulatory elements. J Virol. 1992;66(9):5479–5484.
Popper SJ, Dieng-Sarr A, Travers KU, et al. Lower HIV-2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis. 1999;180:1116–1121.
Arya SK. Human and simian immunodeficiency retroviruses: activation and differential transactivation of gene expression. AIDS Res Hum. Retroviruses. 1988;4:175–186.
Chang Y, Jeang KT. The basic RNA-binding domain of HIV-2 Tat contributes to preferential transactivation of a TAR 2-containing LTR. Nucleic Acids Res. 1992;20:5465–5472.
Malim MH, Hauber J, Le SY, et al. The HIV-1 rev transactivator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature. 1989;338:254–257.
Hammarskjold ML, Heimer J, Hammarskjold B, et al. Regulation of human immunodeficiency virus env expression by the rev gene product. J. Virol. 1989;63:1959–1966.
Emerman M, Vazeux R, Peden K. The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization. Cell. 1989;57(7):1155–1165.
Dayton AI, Terwilliger EF, Potz J, et al. Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus. JAIDS. 1988;1:441–452.
Dillon P, Nelbock P, Perkins A, et al. Structural and functional analysis of the human immunodeficiency virus type 2 rev protein. J Virol. 1991;65:445–449.
Sakai H, Siomi H, Shida H, et al. Functional comparison of transactivation by human retrovirus rev and rex genes. J Virol. 1990;64(12):5833–5839.
Dillon PJ, Nelbock P, Perkins A, et al. Function of the human immunodeficiency virus types 1 and 2 Rev proteins is dependent on their ability to interact with a structured region present in env gene mRNA J Virol. 1990;64:4428–4437.
Garrett ED, Cullen BR. Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2. J Virol. 1992;66(7):4288–4294.
Browning CM, Cagnon L, Good PD, et al. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. J Virol. 1999;73(6):5191–5195.
Allan JS, Coligan J, Lee TH, et al. A new HTLVIII/LAV encoded antigen detected by antibodies from AIDS patients. Science. 1985;230:810–813.
Arya SK, Gallo RC. Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA. 1986;83:2209–2213.
Switzer WM, Wiktor S, Soriano V, et al. Evidence of Nef truncation in human immunodeficiency virus type 2 infection. J Infect Dis. 1998;177(1):65–71.
Lee TH, Coligan J, Allan J, et al. A New HTLVIII/LAV protein encoded by a gene found in cytopathic retroviruses. Science. 1986;231:1546–1549.
Fisher AG, Ensoli B, Ivanoff L, et al. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science. 1987;237:888–893.
Gabuzda D, Lawrence K, Langhoff E, et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 1992;66:6489–6495.
Ohagen A. Role of Vif in stability of HIV-1 core. J Virol. 2000;74:11055–11066.
Tristem M, Marshall C, Karpas A, et al. Origin of vpx in lentiviruses. Nature. 1990;347:341–342.
Yuan X, Matsuda Z, Matsuda M, et al. Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses. 1990;6(11):1265–1271.
Cohen EA, Dehni G, Sodroski JG, et al. Human immunodeficiency virus vpr product is a virionassociated regulatory protein. J Virol. 1990;64:3097–3099.
Yu X-F, Matsuda M, Essex M, et al. Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol. 1990;64:5688–5693.
Hattori N, Michaels F, Fargnoli K, et al. The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages. Proc Natl Acad Sci USA. 1990;87:8080–8084.
Fletcher TM, Brichacek B, Sharova N, et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO Journal. 1996;15(22):6155–6165.
Kewalramani VN, Park CS, Gallombardo PA, et al. Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect. Virology. 1996;218(2):326–334.
Kewalramani VN, Emerman M. Vpx association with mature core structures of HIV-2. Virology. 1996;218(1):159–168.
Marcon L, Michaels F, Hattori N, et al. Dispensable role of the human immunodeficiency virus type 2 Vpx protein in viral replication. J Virol. 1991;65(7):3938–3942.
Hu W, Van der Heyden N, Ratner L. Analysis of the function of viral protein X (VPX) of HIV-2. Virology. 1989;173:624–630.
Shibata R, Miura T, Hayami M, et al. Mutational analysis of the human immunodeficiency virus type 2 (HIV-2) genome in relation to HIV-1 and simian immunodeficiency virus SIVagm. J Virol. 1990;64:742–747.
Yu XF, Yu QC, Essex M, et al. The vpx gene of simian immunodeficiency virus facilitates efficient viral replication in fresh lymphocytes and macrophage. J Virol. 1991;65(9):5088–5091.
Kappes J, Conway J, Lee S, et al. Human immunodeficiency virus type 2 vpx protein augments viral infectivity. Virology. 1991;184:197–209.
Popper S, Sankalé JL, Thior I, et al. Vpx reactivity as a predictor of disease progression in HIV-2 infection. AIDS Res Hum Retroviruses. 1998;14(13):1157–1162.
Voss G, Kirchhoff F, Nick S, et al. Morphogenesis of recombinant HIV-2 gag core particles. Virus Research. 1992;24(2):197–210.
Henderson L, Sowder R, Copeland T, et al. Gag precursors of HIV and SIV are cleaved into six proteins found in the mature virions. J Med Primatol. 1990;19:411–419.
Gorelick RJ, Nigida SM, Bess JW, et al. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J Virol. 1990;64(7):3207–3211.
Komatsu H, Tsukahara T, Tozawa H. Viral RNA binding properties of human immunodeficiency virus type-2 (HIV-2) nucleocapsid protein-derived synthetic peptides. Biochem Molec Bio Intern. 1996;38(6): 1143–1154.
Lee WR, Syu WJ, Du B, et al. Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 1992;89(6):2213–2217.
Lee WR, Yu XF, Syu WJ, et al. Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. J Virol. 1992;66(3):1799–1803.
Leonard CK, Spellman MW, Riddle L, et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Bio Chem. 1990;265(18):10373–10382.
Guyader M, Emerman M, Sonigo P, et al. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987;326:662–669.
Kuhnel H, von Briesen H, Dietrich U, et al. Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate. Proc Natl Acad Sci USA. 1989;86:2383–2387.
Hasegawa A, Tsujimoto H, Maki N, et al. Genomic divergence of HIV-2 from Ghana. AIDS Res Hum Retroviruses. 1989;5(6):593–604.
Kumar P, Hui HX, Kappes JC, et al. Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate. J Virol. 1990;64:890–901.
Klemm E, Schneweis KE, Horn R, et al. HIV-2 infection with initial neurological manifestation. J Neurol. 1988;235:304–307.
Sankalé JL, De La Tour RS, Marlink RG, et al. Distinct quasi-species in the blood and the brain of an HIV-2-infected individual. Virology. 1996;226(2):418–423.
Steffy K, Kraus G, Looney D, et al. Role of the fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2. J Virol. 1992;66;4532–4535.
Robert-Guroff M, Aldrich K, Muldoon R, et al. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J Virol. 1992;66(6):3602–3608.
Bjorling E, Broliden K, Bernardi D, et al. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc. Natl Acad Sci USA. 1991;88:6082–6086.
Nixon DF, Huet S, Rothbard J, et al. An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS. 1990;4(9):841–845.
Cao H, Kanki P, Sankale J-L, et al. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implication for vaccine development. J Virol. 1997;71(11):8615–8623.
Norley SG, Mikschy U, Werner A, et al. Demonstration of cross-reactive antibodies able to elicit lysis of both HIV-1-and HIV-2-infected cells. J Immunol. 1990;145:1700–1705.
Ljunggren K, Chiodi F, Biberfeld G, et al. Lack of cross-reaction in antibody-dependent cellular cytotoxicity between human immunodeficiency virus (HIV) and HIV-related West African strains. J Immunol. 1988;140(2):602–605.
Huang M, Essex M, Lee TH. Localization of immunogenic domains in the human immunodeficiency virus type 2 envelope, J Virol. 1991;65:5073–5079.
Mannervik M, Putkonen P, Ruden U, et al. Identification of B-cell antigenic sites on HIV-2 gp125. JAIDS. 1992;5(2):177–187.
Norrby E, Putkonen P, Bottiger B, et al. Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1. AIDS Res Hum. Retroviruses. 1991;7(3):279–285.
Bjorling E, von Garrelts E, Morner A, et al. Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display. J Gen Virol. 1999;80(Pt 8):1987–1993.
McKnight A, Shotton C, Cordell J, et al. Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol. 1996;70(7):4598–4606.
Weiss RA, Clapham PR, Weber JN, et al. HIV-2 antisera cross-neutralize HIV-1. AIDS. 1988;2:95–100.
Bottiger B, Karlsson A, Andreasson PA, et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135). AIDS Res Hum Retroviruses. 1989;5:525–533.
Mulligan MJ, Ritter GD, Chaikin MA, et al. Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex. Virology. 1992;187:233–241.
Bottiger B, Karlsson A, Andreasson PA, et al. Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site. J Virol. 1990;64:3492–3499.
Holzer T, Allen R, Heynen C, et al. Discrimination of HIV-2 infection from HIV-1 infection by western blot and radioimmuno-precipitation analysis. AIDS Res Hum Retroviruses. 1990;6:515–524.
AIDS: Recommendations for interpretation of HIV-2 western blot results. WHO Weekly Epidemiol Rec. 1990;65:74–5.
Baillou A, Janvier B, Mayer R, et al. Site-Directed Serology Using Synthetic Oligopeptides Representing the C-terminus of the External Glycoproteins of HIV-1, HIV-2, or SIVmac May Distinguish Subtypes Among Primate Lentiviruses. AIDS Res Hum Retroviruses. 1991;7:767–772.
Baillou A, Janvier B, Leonard G, et al. Fine serotyping of human immunodeficiency virus serotype 1 (HIV-1) and HIV-2 infections by using synthetic oligopeptides representing an immunodominant domain of HIV-1 and HIV-2/simian immunodeficiency virus. J Clin Microbiol. 1991;29(7):1387–1391.
Ayres L, Avillez F, Garcia Benito A, et al. Multicenter evaluation of a new recombinant enzyme immunoassay for the combined detection of antibody to HIV-1 and HIV-2. AIDS, 1990;4:131–138.
Broliden PA, Ruden U, Ouattara AS, et al. Specific synthetic peptides for detection of and discrimination between HIV-1 and HIV-2 infection. JAIDS. 1991;4(10):952–958.
Gueye-Ndiaye A, Clark R, Samuel K, et al. Cost-Effective Diagnosis of HIV-1 and HIV-2 By Recombinant-Expressed env Peptide (566/966) Dot Blot Analysis. AIDS. 1993;7:481–495.
Zuber M, Samuel KP, Lautenberger JA, et al. Bacterially produced HIV-2 env polypeptides specific for distinguishing HIV-2 from HIV-1 infections. AIDS Res Hum Retroviruses. 1990;6:525–534.
Andersson S, da Silva Z, Norrgren H, et al. Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2-prevalent area. AIDS. 1997;11(15):1815–1822.
Kanki PJ, Hamel DJ, Sankalé J-L, et al. Human Immunodeficiency Virus Type 1 Subtypes Differ in Disease Progression. J Infect Dis. 1999;179:68–73.
Kanki PJ, Barin F, M’Boup S, et al. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science. 1986;232(4747):238–243.
Tedder R, O’Connor T, Hughs A, et al. Envelope cross-reactivity in western blot for HIV-1 and HIV-2 may not indicate dual infection. Lancet. 1988;2(8617):927–930.
Kanki P, Mboup S, Barin F, et al. The Biology of HIV-1 and HIV-2 in Africa. In: Giraldo G, Beth-Giraldo E, Klumeck N, et al., eds. AIDS and. Associated Cancers in Africa. Basel: S. Karger; 1988:230–236.
Evans L, Moreau J, Odehouri K, et al. Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient. Lancet. 1988;2(8625):1389–1391.
Peeters M, Gershy-Damet GM, Fransen K, et al. Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d’Ivoire. Lancet. 1992;340(8815):339–340.
Rayfield M, De Cock K, Heyward W, et al. Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis. 1988;158:1170–1176.
Dieng-Sarr A, Thior I, Kokkotou E, et al. HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts. AIDS. 1998;12(2):131–137.
Dieng-Sarr A, Popper S, Thior I, et al. Relationship between HIV-2 proviral load and CD4+ lymphocytes differs in HIV monotypic and dual infection. J Hum Virol. 1999;2(1):45–51.
Donnelly C, Leisenring W, Kanki P, et al. Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal. Bull Math Biol. 1993;55(4):731–743.
Hendry R, Parks D, Campos Mello D, et al. Lack of evidence for HIV-2 infection among at-risk individuals in Brazil. JAIDS. 1991;4:623.
Kvinesdal BB, Worm AM, Lindhardt BO, et al. HIV-2 infection in Denmark. Scand J Inf Dis. 1992;24(4):419–421.
Georgoulias V, Agelakis A, Fountouli P, et al. Seroprevalence of HIV-2 infection in Greece (Crete). JAIDS. 1990;3(12):1188–1192.
Costigliola P, Ricchi E, Manfredi R, et al. No evidence of HIV-2 infection amongst HIV-1 Ab positive people in the largest cities of north-eastern Italy. Euro J Epid. 1992;8(1):140–141.
Estebanez P, Sarasqueta C, Rua-Figueroa M, et al. Absence of HIV-2 in Spanish groups at risk for HIV-1 infection. AIDS Res Hum Retroviruses. 1992;8(4):423–424.
Downing RG, Biryahwaho B. No evidence for HIV-2 infection in Uganda. Lancet. 1990;336(8729):1514–1515.
O’Brien TR, George JR, Epstein JS, et al. Testing for antibodies to human immunodeficiency virus type 2 in the United States. MMWR. 1992;41(RR-12):1–9.
Recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. Food and Drug Administration, Center for Biologies Evaluation and Research, Bethesda, MD; 1990.
Dufoort G, Courouce A, Ancelle-Park R, et al. No Clinical Signs 14 years after HIV-2 transmission via Blood Transfusion. Lancet. 1988;2:510.
Kanki P. Epidemiology and Natural History of HIV-2. In: DeVita VJ, Hellman S, Rosenberg S, eds. In AIDS: Etiology, Diagnosis, Treatment, and. Prevention. 4th Edition ed. Philadelphia, PA: J. B. Lippincott Co; 1997:127–135.
Gilbert P, McKeague I, Eisen G, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. 2001 (in press).
Pepin J, Quigley M, Todd J, et al. Association between HIV-2 infection and genital ulcer diseases among male sexually transmitted disease patients in The Gambia. AIDS. 1992;6(5):489–493.
Kanki P, Mboup S, Marlink R, et al. Prevalence and Risk Determinants of Human Immunodeficiency Virus Type 2 (HIV-2) and Human Immunodeficiency Virus Type 1 (HIV-1) in West African Female Prostitutes. Amer J Epidemiol. 1992;136:895–907.
Aaby P, Ariyoshi K, Buckner M, et al. Age of wife as a major determinant of male-to-female transmission of HIV-2 infection: a community study from rural West Africa. AIDS. 1996;10(13):1585–1590.
Morgan G, Wilkins HA, Pepin J, et al. AIDS following mother-to-child transmission of HIV-2. AIDS. 1990;4(9):879–882.
Gayle H, Gnaore E, Adjorlolo G, et al. HIV-1 and HIV-2 infection in children in Abidjan, Cote D’Ivoire. JAIDS. 1992;5:513.
Del Mistro A, Chotard J, Mali A, et al. HIV-1 and HIV-2 seroprevalence rates in mother-child pairs living in The Gambia, West Africa. JAIDS. 1992;5:19–24.
Poulsen AG, Kvinesdal BB, Aaby P, et al. Lack of evidence of vertical transmission of human immunodeficiency virus type 2 in a sample of the general population in Bissau. JAIDS. 1992;5:25–30.
Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group. Pediatr Infect Dis J. 1994;13:502.
Abbott RC, Ndour-Sarr A, Diouf A, et al. Risk Determinants for HIV Infection and Adverse Obstetrical Outcomes in Pregnant Women in Dakar, Senegal. JAIDS. 1994;7:711–717.
O’Donovan D, Ariyoshi K, Milligan P, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. AIDS. 2000;14(4):441–448.
Marlink R, Kanki P, Thior I, et al. Reduced Rate of Disease Development with HIV-2 Compared to HIV-1. Science. 1994:265:1587–1590.
Lisse IM, Poulsen A-G, Aaby P, et al. Immunodeficiency in HIV-2 infection: a community study from Guinea-Bissau. AIDS. 1990;4:1263–1266.
Kestens L, Brattegard K, Adjorlolo G, et al. Immunological comparison of HIV-1, HIV-2 and dually-reactive women delivering in Abidjan, Cote d’Ivoire. AIDS. 1992;6:803–807.
Pepin J, Morgan G, Dunn D, et al. HIV-2-induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1. AIDS. 1991;5:1165–1172.
Lisse IM, Poulsen AG, Aaby P, et al. Serial CD4 and CD8 T-lymphocyte counts and associated mortality in an HIV-2-infected population in Guinea-Bissau. JAIDS. 1996;13(4):355–362.
Traore I, Marlink R, Thior I, et al. HIV-2 as a model for long term non-progression. XI International Conference on AIDS; 1996; Vancouver, Canada.
Victorino R, Guerreiro D, Pinto L, et al. Clinical, immunological and epidemiological assessment of women with indeterminate western blots for HIV antibodies. International Conference on AIDS. 1992;8(3):160 (abstract no. PuC 8046).
Michel P, Balde AT, Roussilhon C, et al. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J Infect Dis. 2000;181(1):64–75.
Cavaleiro R, Sousa A, Loureiro A, et al. Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity. AIDS. 2000;14:2679–2686.
Asjo B, Albert J, Karlsson A, et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. 1986;ii:660–662.
Fenyo E, Albert J, Asjo B. Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS. 1989;3(supp 1):S5–S12.
Mulligan MJ, Kumar P, Hui HX, et al. The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation. AIDS Res Hum Retroviruses. 1990;6:707–720.
Schulz T, Whitby D, Hoad J, et al. Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia. J Virol. 1990;64:5177–5182.
Sankaté JL, MBoup S, Marlink R, et al. HIV-2 and HIV-1 Quasispecies in Cervical Secretions and Blood. AIDS Res Hum Retroviruses. 1998; 14(16):1473–1481.
Simon F, Matheron S, Tamalet C, et al. Cellular and Plasma Viral Load in Patients Infected with HIV-2. AIDS. 1993;7:1411–1417.
Berry N, Ariyoshi K, Jobe O, et al. HIV Type 2 Proviral Load measured by Quantitative Poly-merase Chain Reaction correlates with CD4+ Lymphopenia in HIV Type 2-Infected Individuals. AIDS Res Hum Retroviruses. 1994;10:1031–1037.
Berry N, Ariyoshi K, Jaffar S, et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol. 1998;l(7):457–468.
Soriano V, Gomes P, Holguin A, et al. HIV-2 in Portugal: circulating subtypes, virus isolation, plasma viral load, and clinical spectrum (The HIV-2 Iberian Project). International Conference on AIDS. 1998;12:269 (abstract no. 21154).
Andersson S, Norrgren H, da Silva Z, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. ArchInternal Med. 2000; 160:3286–3293.
Popper SJ, Dieng-Sarr A, Guèye-NDiaye A, et al. Low Plasma HIV-2 viral load is independent of proviral load: low virus production in vivo. J Virol. 2000;74(3):1554–1557.
Clavel F, Guetard D, Brun-Vezinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986;233:343–346.
Saimot AG, Coulaud JP, Mechali D, et al. HIV-2/LAV-2 in Portuguese man with AIDS (Paris, 1978) who had served in Angola in 1968–74. Lancet. 1987;i:688.
De Cock K, Odehouri K, Colebunders R, et al. A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, Cote d’Ivoire. AIDS. 1990;4:443.
Le Guenno BM, Barabe P, Griffet PA, et al, HIV-2 and HIV-1 AIDS Cases in Senegal: Clinical patterns and immunological perturbations. JAIDS. 1991;4(4):421–427.
Schneider J, Luke W, Kirchhoff F, et al. Isolation and characterization of HIV-2 obtained from a patient with predominantly neurological defects. AIDS. 1990;4:455.
Dwyer D, Matheron S, Bakchine S, et al. Detection of human immunodeficiency virus type 2 in brain tissue. J Infect Dis. 1992;166:888.
Marlink RG, Ricard D, M’Boup S, et al. Clinical, hematologic, and immunologic cross-sectional evaluation of individuals exposed to human immunodeficiency virus type 2 (HIV-2). AIDS Res. Hum Retroviruses. 1988;4:137–148.
Diouf K, Dieng-Sarr A, Popper S, et al. HIV-2 and HLA: associations with rate of disease progression. 2001 (in press).
Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999;283:1748–1752.
Kanki P, Essex M, Barin F. Antigenic Relationships Between HTLV-3/LAV, STLV-3, and HTLV-4. In: Chanock RM, Lerner RA, Brown F, et al., eds. Vaccines 87: Modern Approaches to New. Vaccines. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1987:185–187.
Essex M, Kanki P, Barin F, et al. Immunogenicity of HIV-1 and HIV-2 Antigens and Relationship to Disease Development. In: Girard M, Vallette L, eds. 2e Colloque des «Cent Gardes»: Retroviruses. of Human A.I.D.S. and Related Animal Diseases. Paris: Marnes-la-Coquette; 1988:219–220.
Bjorling E, Scarlatti G, von Gegerfelt A, et al. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology. 1993;193(1): 528–530.
Bjorling E, Chiodi F, Utter G, et al. Two neutralizing domains in the V3 region of the envelope glycoprotein gp125 of HIV-2 type 2. J Immunol. 1994;152:1952–1959.
Fenyo EM, Putkonen P. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. Immunology Letters. 1996;51(l–2):95–99.
Belec L, Tevi-Benissan C, Dupre T, et al. Comparison of cervicovaginal humoral immunity in clinically asymptomatic (CDC A1 and A2 category) patients with HIV-1 and HIV-2 infection. J Clin Immunol. 1996; 16(1): 12–20.
Gotch F, McAdam SN, Allsopp CE, et al. Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. J Immunol. 1993;151(6):3361–3369
Bertoletti A, Cham F, McAdam S, et al. Cytotoxic T cells from human Immunodeficiency virus type 2 infected patients frequently cross-react with different human immunodeficiency virus type 1 clades. J Virol. 1998;72(3):2439–2448.
Dieng Sarr A, Lu Y, Sankalé J-L, et al. Robust HIV-2 cellular immune response measured by a modified Anthrax toxin-based ELISPOT assay. AIDS. Res Hum Retroviruses. 2001;17(13):1257–1264.
Travers K, MBoup S, Marlink R, et al. Natural Protection Against HIV-1 Infection Provided by HIV-2. Science. 1995;268:1612–1615.
Travers K, Eisen G, Marlink, R, et al. Protection from HIV-1 infection by HIV-2. AIDS. 1998;12:224–225.
Wiktor SZ, Nkengasong JN, Ekpini ER, et al. Lack of protection against HIV-1 infection among women with HIV-2 infection. AIDS. 1999;13(6):695–699.
Aaby P, Poulsen AG, Larsen O, et al. Does HIV-2 protect against HIV-1 infection? [letter] [see comments]. Comment in: AIDS 1998 Jan 22;12(2):224–5. AIDS. 1997;11(7):939–940.
Ariyoshi K, van der Loeff M, Sabally S, et al. Does HIV-2 infection provide cross-protection against HIV-1 infection? (letter). AIDS. 1997;11(1053–1054).
Norrgren H, Andersson S, Biague AJ, et al. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: no protection of HIV-2 against HIV-1 infection. AIDS. 1999;13:701–707.
Arya SK, Gallo RC. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection. Proc Natl Acad Sci USA. 1996;93(9):4486–4491.
Rappaport J, Arya SK, Richardson MW, et al. Inhibition of HIV-1 expression by HIV-2. J Mole Med. 1995;73(12):583–589.
Dieng-Sarr A, Sankalé J-L, Hamel DJ, et al. Genetic Analysis of HIV Type 2 in Monotypic and Dual HIV Infections. AIDS Res Hum Retroviruses. 2000;16(3):297–300.
Dieng-Sarr A, Sankalé J-L, Hamel DJ, et al. Interaction with Human Immunodeficiency Virus (HIV) Type 2 Predicts HIV Type 1 Genotype. Virology. 2000;268:402–410.
Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nature Medicine. 1996;2(4):412–417.
Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270(5243):1811–1815.
Zagury D LA, Chams V, Fall L, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA. 1998;95:3857–3861.
Lehner T, Wang Y, Cranage M, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Medicine. 1996;2(7):767–775.
Kokkotou EG, Sankalé J-L, Mani I, et al. In vitro correlates of HIV-2 mediated HIV-1 protection. Proc Natl Acad Sci USA. 2000;97(12):6797–6802.
Neoh LP, Akimoto H, Kaneko H, et al. The production of beta-chemokines induced by HIV-2 envelope glycoprotein [letter]. AIDS. 1997;11(8):1062–1063.
Locher CP, Blackbourn DJ, Barnett SW, et al. Superinfection With Human Immunodeficiency Virus Type 2 Can Reactivate Virus Production In Baboons But Is Contained By a Cd8 T Cell Antiviral Response. J Infect Dis. 1997; 176(4):948–959.
Putkonen P, Thorstensson R, Albert J, et al. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS. 1990;4(8):783–789.
Putkonen P, Thorstensson R, Walther L, et al. Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res Hum Retroviruses. 1991;7(3):271–277.
Andersson S, Makitalo B, Thorstensson R, et al. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Inf Dis. 1996;174(5):977–985.
Biberfeld G, Thorstensson R, Putkonen P. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2. AIDS Res Hum Retroviruses. 1996;12(5):443–446.
Myagkikh M, Alipanah S, Markham PD, et al. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses. 1996;12(11):985–992.
De Clercq E, Yamamoto N, Pauwels R, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA. 1992;89(12):5286–5290.
Bottiger D, Putkonen P, Oberg B. Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-fluorothymidine. AIDS Res Hum Retroviruses. 1992;8(7):1235–1238.
Schutten M, van der Ende ME, Osterhaus AD. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2 [letter]. N Eng J Med. 2000;342(23):1758–1760.
Ayanian JZ, Maguire JH, Marlink R, et al. HIV-2 Infection in the United States. N Engl J Med 1989;320:1422–1423.
Clark NM, Dieng-Sarr A, Sankale JL, et al. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy [letter]. AIDS. 1998;12(18):2506–2507.
Rodes B, Holguin A, Soriano V, et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbio. 2000;38(4):1370–1374.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Kanki, P.J., Sankalé, JL., Mboup, S. (2002). Biology of Human Immunodeficiency Virus Type 2 (HIV-2). In: Essex, M., Mboup, S., Kanki, P.J., Marlink, R.G., Tlou, S.D., Holme, M. (eds) AIDS in Africa. Springer, Boston, MA. https://doi.org/10.1007/0-306-47817-X_5
Download citation
DOI: https://doi.org/10.1007/0-306-47817-X_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46699-1
Online ISBN: 978-0-306-47817-8
eBook Packages: Springer Book Archive